Endothelins are potent vasoconstrictors, and much more besides

Trends in Pharmacological Sciences

Volumn 21, Issue 2, 2000, Pages 38-40

  Gray, Gillian A ^a   Battistini, Bruno ^b,c   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 7 [2 (2 CARBOXYPROPYL ) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE; ATRASENTAN; BSF 302146; CGS 35066; CGS 35339; DAGLUTRIL; ENDOTHELIN; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; LU 224332; PD 180988; SB 247083; SCH 54470; SITAXSENTAN; TBC 3214; TEZOSENTAN; UNCLASSIFIED DRUG;

ARRHYTHMOGENESIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CONFERENCE PAPER; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME INHIBITION; INFLAMMATION; MEDIATOR RELEASE; NOCICEPTION; PRIORITY JOURNAL; RECEPTOR BLOCKING; VASOCONSTRICTION;

ASPARTIC ENDOPEPTIDASES; BENZAZEPINES; BENZHYDRYL COMPOUNDS; BENZOFURANS; ENDOTHELIN-1; ENDOTHELINS; ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HUMANS; METALLOENDOPEPTIDASES; PHOSPHONIC ACIDS; PYRIMIDINES; RECEPTORS, ENDOTHELIN; VASCULAR DISEASES; VASOCONSTRICTOR AGENTS;

EID: 0034141296     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(99)01431-5     Document Type: Conference Paper

References (7)

1. Yanagisawa M.et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1998;411-415.
2. Inoue A.et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U. S. A. 86:1989;2863-2867.
3. Ames R.S.et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 401:1999;282-286.
4. Turner A.J.et al. Isoforms of endothelin-converting enzyme: why and where? Trends Pharmacol. Sci. 19:1998;483-486.
5. Gariepy C.E. Transgenic expression of the endothelin-B receptor prevents congenital intestinal aganglionosis in a rat model of Hirschsprung disease. J. Clin. Invest. 102:1998;1092-1101.
6. Sutsch G.et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 98:1998;2262-2268.
7. Krum H.et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. New Engl. J. Med. 338:1998;784-790.